Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

24 of 80+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · P01

  Understanding and targeting treatment-associated lineage plasticity in cancer

  Columbia University Health Sciences· New York, United States· US$2,729,322 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

  Methodist Hospital Research Institute· Houston, United States· US$514,864 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Elucidating upstream and downstream NUAK2 mechanisms in neuroendocrine prostate cancer

  Augusta University· Augusta, United States· US$518,589 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R56

  The role of AKT isoform-preferred substrates in prostate cancer aggressiveness

  Roswell Park Cancer Institute Corp· Buffalo, United States· US$130,125 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  Analysis of epithelial heterogeneity and plasticity in prostate development and cancer

  Columbia University Health Sciences· New York, United States· US$613,866 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

10 of 74 running projects, newest first. Listed amounts together: US$30.6m + €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  High-resolution Intra-operative PSMA PET-CT in Prostate Cancer

  NCT06298838· IRCCS San Raffaele· Updated 6 Nov 2026

  “Difficulties in patient recruitment”Registry text, quoted unchanged. Source

• Withdrawn

  Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT07090369· Peter MacCallum Cancer Centre, Australia· Updated 30 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Terminated

  Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

  NCT05960578· University of Washington· Updated 19 Oct 2026

  “The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.”Registry text, quoted unchanged. Source

• Withdrawn

  Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

  NCT06982222· National Cancer Institute (NCI)· Updated 28 Aug 2026

  “Other - Protocol moved to Withdrawn”Registry text, quoted unchanged. Source

• Suspended

  Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

  NCT06200103· Mayo Clinic· Updated 20 Aug 2026

  “Pending additional funding.”Registry text, quoted unchanged. Source

• Terminated

  Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

  NCT05995236· Methodist Health System· Updated 4 Aug 2026

  “So far, we have not been able to collect meaningful data for these patients which also led to our decision to close this study before attempting write up and publish any results”Registry text, quoted unchanged. Source

• Terminated

  High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy

  NCT04461509· Alessandro D'Agnolo· Updated 22 Jul 2026

  “Funding ceased before all specimen collection and analysis could be completed”Registry text, quoted unchanged. Source

• Suspended

  Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient

  NCT05422105· Primo Biotechnology Co., Ltd· Updated 6 Jul 2026

  “Interim Analysis”Registry text, quoted unchanged. Source

• Terminated

  Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).

  NCT04745871· University Hospital, Brest· Updated 11 Jun 2026

  “In the PREOP-PSMA protocol, written before 68Ga-PSMA-11 obtained Marketing Authorization. Today, PSMA PET/CT has become routine and is performed before MTB review.”Registry text, quoted unchanged. Source

• Terminated

  68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

  NCT04716725· Thomas Hope· Updated 15 May 2026

  “Low accrual”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

  NCT06894511· Novartis Pharmaceuticals· Source

• Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

  NCT07914855· National Cancer Institute (NCI)· Source

• A clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

  2024-512340-32-01· Novartis Pharma AG· Source

• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT04221542· Amgen· Source

• Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

  NCT06004661· Novartis Pharmaceuticals· Source

• 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

  NCT04689828· Novartis Pharmaceuticals· Source

• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Novartis Pharmaceuticals· Source

• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

  NCT03972657· Regeneron Pharmaceuticals· Source

• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

  NCT06095089· Janssen Research & Development, LLC· Source

• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Janssen Research & Development, LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Concordant RNA-protein evidence and human tissue metabolomics prioritize UPP1-associated nucleotide remodeling in prostate cancer.

  PLoS One, Jul 2026

• Urinary and cellular volatile organic compounds as biomarkers for urological cancers: a systematic review of GC-MS-based volatolomics.

  Metabolomics, Jul 2026

• Circulating metabolite biomarkers associated with prostate cancer risk in Black Americans: findings from the Southern Community Cohort Study.

  Br J Cancer, Jun 2026

• Multi-omics integration predicts the incidence of 17 diseases in the UK Biobank.

  Nat Commun, May 2026

• Rapid Noninvasive Classification of Prostatic Disease Using Paper Spray Ionization Mass Spectrometry (PSI-MS)-Based Nontargeted Metabolomics.

  Anal Chem, Apr 2026

• An enrichment-based approach to interpreting metabolomic data using differential metabolomic profiles within the iDMET framework.

  BMC Bioinformatics, Apr 2026

• Effects of daily multivitamin-multimineral supplementation on metabolomic profiles: 2-year findings from the COSMOS randomized clinical trial.

  Geroscience, Mar 2026

• Activating NK cell immunity against prostate cancer with Hedysarum polybotrys Hand.-Mazz.: A multi-omics integration of computational prediction and experimental validation on PI3K/AKT and PD-1/PD-L1 axes.

  J Ethnopharmacol, Mar 2026

• Cell metabolomics to reveal the mechanism of saponins and alkaloids on prostate inflammation via COX and LOX pathways.

  Prostaglandins Other Lipid Mediat, Mar 2026

• Prostate cancer: metabolic remodelling in expressed prostatic secretions reveals cellular structural changes measured by mpMRI.

  Mol Omics, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.